Mirum Pharmaceuticals, Inc. (MIRM) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary reflects strong financial performance with 55% YoY sales growth and improved cash position. Product development is promising, with milestones and international expansion underway. The Q&A section addressed potential risks effectively, showing management's confidence in overcoming challenges. Despite operational risks, the positive financial metrics and optimistic guidance suggest a potential stock price increase. The market cap indicates a moderate reaction is likely, so a 'Positive' sentiment is justified.
Key Financial Performance
Net Product Sales (2025) $521 million, a 55% year-over-year growth from $336 million in 2024. The increase was driven by strong performance in LIVMARLI sales in the U.S. ($245 million) and internationally ($115 million), as well as $161 million from bile acid medicines. Growth was attributed to leadership in Alagille syndrome, accelerating PFIC uptake, and growing international demand.
Net Product Sales (Q4 2025) $149 million, compared to $99 million in Q4 2024, reflecting a significant increase due to the same factors driving annual growth.
Operating Expense (2025) $543 million, including R&D expense of $186 million, SG&A expense of $257 million, and cost of sales of $100 million. Noncash expenses included $95 million in stock-based compensation and intangible amortization.
Commercial Cash Contribution Margin (2025) Approximately 55%, a significant increase from the prior year, reflecting improved operational efficiency.
Cash, Cash Equivalents, and Investments (End of 2025) $391 million, up from $293 million at the end of 2024, driven by solid operating performance and private placements generating $268.5 million.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
LIVMARLI net product sales: $245 million in the U.S., $115 million internationally
Bile acid medicines: Contributed $161 million in net product sales
CTEXLI approval: Approved for CTX and a tablet formulation of LIVMARLI
Pipeline expansion: Addition of Phase III Brelovitug program for chronic hepatitis delta virus
International market growth: Strong demand and growth in international markets for LIVMARLI
Market leadership: Continued leadership in Alagille syndrome and accelerating PFIC uptake
Net product sales growth: Achieved $521 million in 2025, exceeding guidance, with a 55% year-over-year growth
Cash position: Ended 2025 with $391 million in cash, up from $293 million in 2024
Commercial cash contribution margin: Improved to 55% in 2025
R&D investment: Increased R&D expenses for Brelovitug clinical program and manufacturing scale-up
Pipeline milestones: Four potentially registrational clinical readouts expected in the next 18 months
Integration of Bluejay acquisition: Smooth integration with $268.5 million raised to support acquisition
Focus on rare diseases: Positioned as a leading rare disease company with a $4 billion revenue potential portfolio
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Risks: The company faces regulatory risks associated with the approval of its drugs, including the need to meet FDA and other international regulatory requirements for its clinical trials and product launches. Failure to meet these requirements could delay or prevent product approvals.
Pipeline Development Risks: The success of the company's pipeline depends on the outcomes of clinical trials, including the VISTAS study for Volixibat and the AZURE studies for Brelovitug. Negative or inconclusive results could impact the company's ability to bring these products to market.
Financial Risks: The company anticipates increased R&D expenses in 2026, particularly for the Brelovitug clinical program and manufacturing scale-up. While these expenses are funded, they could strain financial resources if revenue growth does not meet expectations.
Market Competition: The company operates in a competitive market for rare disease treatments. New entrants or existing competitors could impact market share and revenue growth.
Integration Risks: The integration of the Brelovitug program and its associated team poses operational risks. Any delays or inefficiencies in integration could affect the program's success and overall company performance.
Supply Chain Risks: Manufacturing validation and scale-up for Brelovitug and other products could face challenges, potentially delaying product availability and impacting revenue.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Expectations: Mirum expects to deliver net product sales of $630 million to $650 million for 2026, building on the $521 million achieved in 2025.
Pipeline Developments: The company anticipates 4 potentially registrational clinical readouts over the next 18 months, including data from the Volixibat VISTAS study in PSC (Q2 2026), interim results from the AZURE-1 study of Brelovitug in hepatitis delta (Q2 2026), and top-line results from the AZURE-1 and AZURE-4 Phase III trials (H2 2026).
Clinical Trials: Enrollment in the Phase III EXPAND study for additional rare cholestatic conditions and the VANTAGE study in PBC is progressing ahead of expectations, with results expected in Q4 2026 and H1 2027, respectively. The BLOOM Phase II study of MRM-3379 in Fragile X syndrome is on track for data in 2027.
R&D Investments: R&D expenses are expected to increase in 2026, driven by investments in the Brelovitug clinical program and manufacturing scale-up for an anticipated BLA submission in 2027.
Financial Outlook: The company expects a return to positive cash flow in 2027, supported by disciplined spending and a strong balance sheet.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How is the company thinking about pricing Volixibat, especially in the context of PSC and PBC opportunities?
A:The company is using PPARs in PBC as a planning benchmark but has not made a final decision. Pricing will be determined closer to launch, considering that there are no other approved medicines for PSC, which gives Volixibat a unique positioning.
Q:Does the episodic nature of itch in PSC patients pose a risk to the upcoming PSC trial?
A:The company acknowledges variability in pruritus perspectives between KOLs and patients. They are enrolling patients with persistent pruritus and tracking pruritus response throughout the study, ensuring the design addresses significant symptoms for patients.
Q:What are the key similarities and differences between the VISTAS and VANTAGE study designs for PSC?
A:Both studies focus on cholestatic pruritus, which is common in intrahepatic cholestasis. The baseline pruritus scores for PSC are expected to be in the moderate-to-severe range, similar to PBC interim data.
Q:What are the FDA safety database requirements for Volixibat, and how do they impact the timing of a potential NDA submission?
A:The FDA has confirmed safety database requirements, particularly for PBC, and acknowledges that PSC is a smaller setting. The current VISTAS PSC study is expected to meet these requirements, with an NDA submission planned for the second half of the year after top-line data.
Q:How will the EXPAND study data on pruritus be broken out, and how does the pruritus bar compare to PFIC and Alagille?
A:The data will likely be broken out by biliary atresia and other smaller settings. The pruritus bar is expected to be similar across settings with elevated bile acids and cholestatic pruritus, as seen in compassionate use examples.
Q:How does the company view label expansion for EXPAND, and how well diagnosed are the additional settings?
A:The label will reflect the basket trial design, excluding larger settings like PSC. The additional settings, particularly in pediatrics, are well diagnosed and symptomatic, with demand evident from compassionate use requests.
Q:What is driving the 2025 sales growth guidance, and how does it split between LIVMARLI and the bile acid portfolio?
A:The growth is primarily driven by LIVMARLI, with steady growth expected in the bile acid portfolio. Japan's revenues will be lower this year due to last year's inventory buildup, despite a successful launch.
Q:What learnings from the EMBARK study are being applied to EXPAND, and what is the market size for the EXPAND basket?
A:EXPAND focuses on older biliary atresia patients with persistent post-Kasai cholestatic pruritus, unlike the acute setting in EMBARK. The U.S. market for EXPAND is estimated at 500+ patients, potentially representing 1/3 of LIVMARLI's $1 billion+ peak potential.
Q:What is the current market for HDV, and how much will R&D increase this year for HDV studies?
A:The U.S. has no labeled treatments for HDV, but the landscape is evolving with potential approvals. The company anticipates a $150 million increase in R&D spend for Brelovitug, with half allocated to CMC investments.
Q:Review of Unclear Management Responses
A:No questions were identified where management avoided giving a direct answer or lacked clarity in their responses.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ALT
AZURE study
BLOOM Phase
Finance Investor
Full Conference
II study
III program
III study
LIVMARLI
Mirium
Pharmaceuticals Full
Phase II
Phase III
Strategic
VISTAS
Volixibat PSC
acquisition
addition
amortization noncash
closing
efficacy
endpoint FDA
hepatitis delta
line result
portion study
press release
registration
result AZURE
study hepatitis
study patient
term readout
track line
week
MIRM Transcript
Mirum Pharmaceuticals, Inc. (MIRM) Q4 2025 Earnings Call Transcript
Positive2-25
The earnings call summary reflects strong financial performance with 55% YoY sales growth and improved cash position. Product development is promising, with milestones and international expansion underway. The Q&A section addressed potential risks effectively, showing management's confidence in overcoming challenges. Despite operational risks, the positive financial metrics and optimistic guidance suggest a potential stock price increase. The market cap indicates a moderate reaction is likely, so a 'Positive' sentiment is justified.
Mirum Pharmaceuticals, Inc. (MIRM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-14
Mirum Pharmaceuticals, Inc. (MIRM) Presents at Evercore 8th Annual Healthcare Conference Transcript
Neutral12-2
Mirum Pharmaceuticals, Inc. (MIRM) Q3 2025 Earnings Call Transcript
Positive11-4
The earnings call reflects a positive outlook with the company's first-ever positive net income, increased cash reserves, and raised revenue guidance for 2025. The Q&A section reveals confidence in product development and competitive positioning, despite some uncertainties in pricing strategies and guidance. The market cap suggests a moderate reaction, leading to an expected stock price increase of 2% to 8%.
MIRM Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
